Biology and clinical application of CAR T cells for B cell malignancies Journal Article


Authors: Davila, M. L.; Sadelain, M.
Article Title: Biology and clinical application of CAR T cells for B cell malignancies
Abstract: Chimeric antigen receptor (CAR)-modified T cells have generated broad interest in oncology following a series of dramatic clinical successes in patients with chemorefractory B cell malignancies. CAR therapy now appears to be on the cusp of regulatory approval as a cell-based immunotherapy. We review here the T cell biology and cell engineering research that led to the development of second generation CARs, the selection of CD19 as a CAR target, and the preclinical studies in animal models that laid the foundation for clinical trials targeting CD19+ malignancies. We further summarize the status of CD19 CAR clinical therapy for non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia, including their efficacy, toxicities (cytokine release syndrome, neurotoxicity and B cell aplasia) and current management in humans. We conclude with an overview of recent pre-clinical advances in CAR design that argues favorably for the advancement of CAR therapy to tackle other hematological malignancies as well as solid tumors. © 2016, The Japanese Society of Hematology.
Keywords: immunotherapy; chimeric antigen receptor; cd19; adoptive t cell therapy; t cell engineering
Journal Title: International Journal of Hematology
Volume: 104
Issue: 1
ISSN: 0925-5710
Publisher: Springer Japan KK  
Date Published: 2016-07-01
Start Page: 6
End Page: 17
Language: English
DOI: 10.1007/s12185-016-2039-6
PROVIDER: scopus
PUBMED: 27262700
PMCID: PMC5512169
DOI/URL:
Notes: Review -- Export Date: 2 August 2016 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Michel W J Sadelain
    456 Sadelain